Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLARINEX-D 12 HOUR vs ACTIDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Relief of symptoms associated with seasonal allergic rhinitis,Relief of symptoms associated with perennial allergic rhinitis,Relief of nasal congestion and sinus pressure
Allergic rhinitis,Allergic conjunctivitis,Urticaria,Angioedema
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Desloratadine: primarily metabolized by CYP3A4 and CYP2D6 to active metabolite 3-hydroxydesloratadine. Pseudoephedrine: partially metabolized in liver by N-demethylation via CYP450 enzymes; largely excreted unchanged in urine.
Hepatic via CYP450 isoenzymes (primarily CYP3A4 and CYP2D6); undergoes N-demethylation and N-oxidation.
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Desloratadine: 83-87% (mainly albumin); pseudoephedrine: negligible binding.
Approximately 90% bound to plasma proteins, primarily albumin.
Desloratadine: 49 L (approx. 0.7 L/kg), extensive tissue distribution; pseudoephedrine: 2.6-3.5 L/kg.
2.5-4.0 L/kg, indicating extensive tissue distribution.
Desloratadine: 100% (oral); pseudoephedrine: ~100% (oral).
Oral bioavailability is approximately 50-60% due to first-pass metabolism.
Contraindicated in patients with GFR < 60 m L/min due to pseudoephedrine component.
GFR 10-50 m L/min: 2.5 mg every 6-8 hours; GFR <10 m L/min: 2.5 mg every 8-12 hours.
No specific Child-Pugh based adjustments for desloratadine; pseudoephedrine may require caution in severe hepatic impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Not recommended for use in pediatric patients under 12 years of age.
Children 2-5 years: 1.25 mg orally every 4-6 hours (max 5 mg/day); Children 6-12 years: 1.25-2.5 mg every 4-6 hours (max 7.5 mg/day).
Use with caution; initiate at lower doses due to increased sensitivity to pseudoephedrine and risk of anticholinergic effects.
Initiate at 1.25 mg orally every 6-8 hours; maximum 5 mg per day due to increased risk of anticholinergic effects and renal impairment.
None.
None
Cardiovascular effects: Use with caution in patients with hypertension, arrhythmias, or ischemic heart disease.,CNS stimulation: May cause insomnia, dizziness, or nervousness.,Urinary retention: Use with caution in patients with prostatic hypertrophy or bladder neck obstruction.,Renal impairment: Reduce dose or avoid in severe renal impairment.,Hepatic impairment: Caution in severe hepatic disease.
May cause drowsiness and impair mental alertness,Avoid alcohol and other CNS depressants,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Elderly patients are more susceptible to anticholinergic effects
Hypersensitivity to desloratadine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Concurrent use with MAO inhibitors or within 14 days of stopping MAOI,Narrow-angle glaucoma,Urinary retention,Breastfeeding
Hypersensitivity to any component,Concurrent use with monoamine oxidase inhibitors
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented foods) as pseudoephedrine may potentiate pressor effects. Taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice; it may increase desloratadine levels. Limit caffeine intake as it can add to CNS stimulation.
No specific food interactions, but taking with food may reduce GI side effects. Alcohol should be strictly avoided due to additive CNS depression. Grapefruit juice is not documented to interact.
Clarinox-D 12 Hour (desloratadine/pseudoephedrine) is classified as FDA Pregnancy Category C. Desloratadine: No adequate studies in pregnant women; animal studies show no teratogenicity at doses 210 times human exposure, but potential for adverse effects is unknown. Pseudoephedrine: Case reports suggest possible association with gastroschisis at first-trimester exposure; vasoconstriction may reduce uteroplacental blood flow, especially in third trimester. Avoid in first trimester if possible; use only if benefit outweighs risk.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergic effects may cause neonatal tachycardia, irritability, and withdrawal symptoms if used near term.
Desloratadine: Excreted into breast milk; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. Pseudoephedrine: Excreted into breast milk; estimated infant dose ~2-7% of maternal dose; may cause irritability, sleep disturbance. M/P ratio: not reported for desloratadine; pseudoephedrine M/P ~3.0. Manufacturer recommends caution due to pseudoephedrine's effects.
Excretion into breast milk likely but negligible amounts; no adverse effects reported in infants. M/P ratio not established. Considered compatible with breastfeeding; monitor for sedation or irritability in neonate.
No specific dose adjustments required for desloratadine; pregnancy may increase volume of distribution but no clinical studies. Pseudoephedrine: Pregnancy may reduce clearance; no formal dose adjustment but use lowest effective dose and shortest duration. Monitor for hypertension.
No specific dose adjustments required in pregnancy; however, use lowest effective dose due to potential anticholinergic effects. Pharmacokinetics may be altered (increased volume of distribution), but no dose adjustment recommended.
CLARINEX-D 12 HOUR (desloratadine/pseudoephedrine) combines a non-sedating antihistamine with a sympathomimetic decongestant. Pseudoephedrine can cause hypertension, tachycardia, and urinary retention; avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Desloratadine is the active metabolite of loratadine; it is less sedating than first-generation antihistamines. The 12-hour formulation requires twice-daily dosing. Monitor for CNS stimulation and insomnia, especially in elderly or pediatric patients.
ACTIDIL (triprolidine) is a first-generation antihistamine with sedative properties. Use cautiously in elderly due to risk of confusion, urinary retention, and falls. Avoid in patients with narrow-angle glaucoma, BPH, or asthma. Administer with food if GI upset occurs. Onset of action is 30-60 minutes; duration 4-6 hours.
Take one tablet every 12 hours with a full glass of water; do not crush or chew.,Do not exceed 2 tablets in 24 hours.,Avoid alcohol and other CNS depressants while taking this medication.,May cause dizziness or drowsiness; avoid driving until you know how the medication affects you.,Notify your doctor if you have high blood pressure, heart disease, thyroid problems, or difficulty urinating.,Discontinue use and seek medical attention if you experience chest pain, rapid heartbeat, or difficulty breathing.,Do not take with other decongestants or antihistamines without consulting a healthcare provider.
Do not drive or operate heavy machinery until you know how this medication affects you; it can cause drowsiness.,Avoid alcohol and other CNS depressants, as they may increase sedation.,Take exactly as prescribed; do not exceed recommended dose.,If you miss a dose, skip it; do not double the next dose.,Notify your doctor if you experience blurred vision, difficulty urinating, or severe drowsiness.,Do not use for prolonged periods without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLARINEX-D 12 HOUR vs ACTIDIL, answered by our medical review team.
CLARINEX-D 12 HOUR is a Antihistamine/Decongestant Combination that works by Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.. ACTIDIL is a Antihistamine that works by H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLARINEX-D 12 HOUR and ACTIDIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLARINEX-D 12 HOUR is: 1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.. The standard adult dose of ACTIDIL is: 2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLARINEX-D 12 HOUR and ACTIDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLARINEX-D 12 HOUR is classified as Category C. Clarinox-D 12 Hour (desloratadine/pseudoephedrine) is classified as FDA Pregnancy Category C. Desloratadine: No adequate studies in pregnant women; animal studies show no teratogen. ACTIDIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.